Aptose Biosciences Inc.

TSX:APS Canada Healthcare — Biotechnology

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors inclu…

14 employees aptose.com

Click to toggle · Cmd+Click for exclusive

Transactions 2026-05-29 M&A

Open PDF

Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical

News release - English.pdf

Results 2026-05-13

Open PDF

Aptose Reports First Quarter 2026 Results

News release - English.pdf

Results 2026-05-13

Open PDF

Interim MD&A - English.pdf

Results 2026-05-13

Open PDF

Interim financial statements/report – English.pdf

Transactions 2026-04-30 M&A

Open PDF

Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical

News release - English.pdf

Ownership 2026-04-01

Other securityholders documents - English.pdf

Results 2026-03-31

Annual report on form 10-K - English.pdf

Results 2026-03-31

Open PDF

Annual MD&A - English.pdf

Results 2026-03-31

Open PDF

Audited annual financial statements – English.pdf

Transactions 2026-03-23 M&A

Open PDF

Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement

News release - English.pdf

Transactions 2026-03-19 M&A

Open PDF

Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical

News release - English.pdf

News 2026-03-05

Other.pdf

News 2026-03-05

Other.pdf

News 2026-03-05

Other.pdf

Transactions 2026-03-03

Other material contracts - English.pdf

Transactions 2026-03-03

Material document(s).pdf

Transactions 2026-03-03 M&A

Open PDF

Aptose Biosciences Inc. announces amended and restated arrangement agreement and second amended and restated 2025 facility agreement

Material change report - English.pdf

News 2026-02-25

Other.pdf

Transactions 2026-02-24 M&A

Open PDF

Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders

News release - English.pdf

News 2026-02-18

Other.pdf

News 2026-02-11

Other.pdf

News 2026-01-15

Other.pdf

Transactions 2025-12-19 M&A

Open PDF

Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC

News release - English.pdf

News 2025-12-08

Other.pdf

Results 2025-12-07

Open PDF

Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

News release - English.pdf

Transactions 2025-11-24